ArticleOncotarget2017
Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.
Jingwei Shao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleOncotarget2017
Jingwei Shao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.